Physician profile
Michael Escobar
NPI 1912437260
$2,483.59
in general payments reported to CMS, 2019-2025
24 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $809 · 2022: $441 · 2023: $670 · 2024: $180 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.83 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $694.73 | 2021-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $362.43 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $198.25 | 2021-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $189.92 | 2021-2023 | |
| Amgen INC. | $162.87 | 2022-2024 | Otezla, Repatha, Evenity |
| Madrigal Pharmaceuticals | $131.96 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $106.01 | 2021-2022 | |
| Pfizer INC. | $69.97 | 2021-2023 | |
| Dynavax Technologies Corporation | $69.74 | 2021-2023 | Heplisav-B |
| Exact Sciences Corporation | $66.83 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $55.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $54.20 | 2022-2023 | |
| Lilly USA, LLC | $50.24 | 2023 | Mounjaro, Emgality, Jardiance |
| Hologic Sales and Service, LLC | $46.29 | 2022-2023 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Lucid Diagnostics INC. | $45.26 | 2022-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $33.49 | 2021-2023 | Korlym |
| Biogen, INC. | $24.35 | 2021 | |
| Abbvie INC. | $21.05 | 2022 | |
| Eisai INC. | $20.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Amneal Pharmaceuticals LLC | $16.74 | 2021 | |
| Gilead Sciences, INC. | $16.20 | 2021 | |
| Glaxosmithkline, LLC. | $14.22 | 2022 | |
| Medtronic, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.